C3PO: advanced Concept for laser uplink/ downlink CommuniCation with sPace Objects represents a radical improvement in performance of existing ground to low earth orbit communication systems in terms of weight reduction, on-board power consumption, data rate and communication security & confidentiality. C3PO in figures: - Mass reduction by a factor 14 - On-board power consumption reduction by a factor 100 - Data rate increase by a factor 2 The project's objectives are to - Design a solution to improve actual downlink and uplink communication systems based on a non-space disruptive technology - Improve enabling Space Surveillance & Tracking technologies performances to meet the final system needs - Increase the Multiple Quantum Well Technology Readiness Level from 2 to 4 - Improve the overall perfromance of space communication systems - Identify the C3PO system market and Business Model - Increase the system safety (including regulation and governance issues) This is achieved through an operational analysis of the final system, the validation of major system parameters through 2 experiments, the consolidation of the system architecturen the elaboration of the associated development roadmap and the definition of the system Business Model. The Multiple Quantum Well retro-reflector technology, derived from non-space domain, is incorporated into the current state of the art as a high-rate lightweight communication device. Its development in the space sector has a disruptive impact on the satellites and satellite imagery markets, enabling new missions such as CubeSat earth observations. The proposed project serve the Union's Common Security & Defence Policy by increasing the satellite communications security. C3PO mobilises traditional space actors and non-space actors such as TEMATYS (SME) and ACREO (Research).

Paper-based printed electronics are new recyclable electronic devices with technical, economic and environmental advantages. Additionally, nanocellulose (NC) based printed electronics, produced mainly from wood pulp, offer better printability and performance than paper. Therefore, the integration of NC-based printed electronics and biosensors is a promising source of innovation in the biomedical industry. In GREENSENSE we propose the development of a sustainable NC-based biosensing platform for Drug-of-Abuse (DoA) analysis, that integrates high-added value printed electronic components (a new biosensor, an NFC communication system, an energy storage system and a display) with a silicon microchip to provide it with multi sensor data processing, autonomy and wireless communication and that is easy for the user to read. The main goal of the project will be the use of NC as: substrate for the printed electronics, lamination film for the encapsulation of the final device and as active component in the formulation of functional inks (conductive, electrochemical, electrolyte and dielectric). In all cases the NC surface will be functionalized to be printable, with good barrier properties and compatible with the functional inks (bioactive, conductive, dielectric, electrochemical, electrochromic and electrolyte). Pilot lines and high throughput, high precision and cost-effective S2S screen-printing and ink-jet printing techniques will be used to produce materials and components at large-scale. Two types of DoA biosensing platforms to eradicate the consume of drugs among the society will be developed: a strip-based platform (2nd generation) that will be connected to a Smartphone and a strip+reader-based platform (3rd generation) that will also include a display. The final flexible and recyclable NC-based biosensing platform will be mass producible with ultra-low power consumption and, therefore, cost-effective, sustainable and environmentally friendly.

Reducing lead times of new medicinal drugs to the market by reducing process development and clinical testing timeframes is a critical driver in increasing European (bio)pharmaceutical industry competitiveness. Despite new therapeutic principles (e.g. the use of pluripotent stem cells, regenerative medicine and treatments based on personalised medicine or biosimilars) or regulatory initiatives to enable more efficient production, such as Quality by design (QbD) with associated Process Analytical Technology (PAT) tools , the slow progress in the development of new bioactive compounds still limits the availability of cheap and effective medicines. In addition, the competitiveness of European (bio)pharma industry is impacted by the unavailability of suitably trained personnel. Fundamental changes in the education of scientists have to be realised to address the need for changes in the traditional ‘big pharma’ business model and the focus on ‘translational medicine – more early stage clinical trials with patients, more external innovation and more collaboration’ . These changes in education should be based on combining cutting-edge science from the early stage of product development through to manufacturing with innovation and entrepreneurship as an integral part of the training. The Rapid Bioprocess Development ITN, employing 15 ESRs, brings together industrialist and academic experts with its main aim to address this critical need by developing an effective training framework in rapid development of novel bioactive molecules from the very early stages of potency and efficacy testing to the biomanufacturing process characterisation and effective monitoring. The main focus of the research is on oncology related proteins and recombinant proteins to be used in diabetes treatment, although the resulting monitoring and modelling methods will be applicable to other bioactive molecule process development as demonstrated by validation on a range of relevant bioactives.